Skip to main content
. 2020 Jan 27;64(2):e01730-19. doi: 10.1128/AAC.01730-19

TABLE 2.

Population PK model parameter estimates and covariate effects associated with the final model for gentamicina

Parameter Value RSE (%)c BSV CV (%) RSE (%)c BOV CV (%) RSE (%)c
CL (liters/h/62.8 kg NFM)b 4.58 1.55 16.5 17.1 20.7 5.62
V1 in oncology patients (liters/57.5 kg NFM)b 18.1 2.43 23.8 22.9
V1 in nononcology patients (liters/57.5 kg NFM)b 21.4 4.78 26.0 31.9
Q in oncology patients (liters/h/56.1 kg NFM) 0.57 4.88 29.4 40.0
Q in nononcology patients (liters/h/56.1 kg NFM) 0.84 12.2 59.8 38.4
V2 (liters/56.1 kg NFM) 18.2 13.6 67.6 35.6
Covariate model
    θserum creatinine 0.58 4.26
    Ffat on CL 0.48 27.2
    Ffat on V1 0.10 31.7
    Ffat on Q 0 fix
    Ffat on V2 0 fix
Residual-error model
    Proportional (%) 29.3 2.21
    Additive (mg/liter) 0.05 16.9
a

BOV, between-occasion variability; BSV, between-subject variability; CV, coefficient of variation; Ffat, fat factor; FFM, fat-free mass; NFM, normal fat mass; OFV, objective function value; Q, intercompartmental clearance; V1, volume of distribution of the central compartment; V2, volume of distribution of the peripheral compartment.

b

For clearance (CL), standard NFM (NFMstd) is calculated as NFMstd = 56.1 + 0.48 × (70 − 56.1) = 62.8 kg; for V1, standard NFM is calculated as NFMstd = 56.1 + 0.10 × (70 − 56.1) = 57.5 kg.

c

Relative standard errors (RSE) for both fixed- and random-effect values were obtained using the sampling importance resampling (SIR) method.